Eli Lilly and Company (LLY), Friday announced that its new long-term data of EBGLYSS study showed durable skin clearance and relief from persistent itch for up to four years for patients with moderate-to-severe atopic dermatitis.
During the open-label extension study, 75% of patients achieved a high bar of near-complete skin clearance, and 78% experienced significant itch relief.
Notably, the safety of EBGLYSS in the first year of the ADlong study was consistent with the known profile in patients with moderate-to-severe atopic dermatitis, regardless of dose frequency, and no new safety signals were observed.
The company holds the exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Meanwhile, its partner Almirall has licensed the rights to develop and commercialize EBGLYSS for the treatment of dermatology indications, including atopic dermatitis, in Europe.
In the pre-market hours, LLY is trading at $894.77, down 0.21 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.